Creative Planning’s Crinetics Pharmaceuticals CRNX Stock Holding History

Creative Planning’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-40,476	Closed	-$1.51M	–	4442
2026 Q2	$1.51M	Sell	40,476 -13,161	-25%	-$489K	﹤0.01%	2316
2026 Q1	$1.95M	Buy	53,637 +6,316	+13%	+$282K	﹤0.01%	1903
2025 Q4	$2.2M	Buy	47,321 +6,749	+17%	+$300K	﹤0.01%	1651
2025 Q3	$1.69M	Buy	40,572 +12,103	+43%	+$387K	﹤0.01%	1671
2025 Q2	$819K	Sell	28,469 -1,445	-5%	-$44.6K	﹤0.01%	2026
2025 Q1	$1M	Buy	29,914 +3,078	+11%	+$115K	﹤0.01%	1712
2024 Q4	$1.37M	Buy	26,836 +7,028	+35%	+$393K	﹤0.01%	1404
2024 Q3	$1.01M	Buy	19,808 +6,811	+52%	+$351K	﹤0.01%	1500
2024 Q2	$582K	Buy	12,997 +2,224	+21%	+$103K	﹤0.01%	1827
2024 Q1	$504K	Buy	+10,773	New	+$422K	﹤0.01%	1842

Other funds holding CRNX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Creative Planning's CRNX Position: Q3 2026 in Review

Creative Planning sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2026, closing a stake of 40,476 shares — an estimated $1.51M sold.

Creative Planning first reported a position in CRNX in Q1 2024 and held it in 10 quarters. The position peaked at $2.2M in Q4 2025. 2 funds tracked by Wall St. Rank hold CRNX as of Q3 2026.

Creative Planning reported no remaining Crinetics Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Creative Planning sold 40,476 Crinetics Pharmaceuticals shares in Q3 2026, an estimated $1.51M.
Creative Planning first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 10 quarters.
Creative Planning's Crinetics Pharmaceuticals position peaked at $2.2M in Q4 2025.
2 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2026.

Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.